Cilostazol protects against myocardial ischemia and reperfusion injury by activating transcription factor EB (TFEB)

Jiangjin Li,Xiaoli Xiang,Zuo Xu
DOI: https://doi.org/10.1002/bab.1754
2019-05-01
Biotechnology and Applied Biochemistry
Abstract:Although cilostazol was proved to have anti‐tumor biological effects. its function in myocardial ischemia and reperfusion (I/R) injury and the underlying mechanisna were not fully illustrated yet. In this study, a rat model of I/R injurywas constructed and qRT‐PCR, Western blot and Immunofluorescence (IF) assay were performed. Our results showed that cilostazol increased LC3 II/LC3 I ratio, reduced p62 abundanceand promoted the expressions of LAMP1, LAMP2, cathepsin B and cathepsin D, indicating that cilostazol could activate autophagy and elevated lysosome activation.Following analysis showed that cilostazol enhanced nuclear protein expression of transcrption factor EB (TFEB), an important regulator of autophagy‐lysosome pathway. Furthermore, CCI‐779, an inhibitor of TFEB, could reverse the effects of cilostazol on autophagic activity and lysosome activation. Importantly, cilostazol suppressedI/R injury‐induced apoptosis by decreasing the cleavage of caspase 3 and PARP. ELISA assay showed that cilostazol reduced the serumlevels of CTn1 and CK‐MB.And decreased infract size caused by I/R injuries. Altogether, this study suggested that cilostazol protects against I/R injury by reulating autophagy, lysosome and apoptsis in a rat model of I/R injury. The underlying mechanism was st leastly, partially through increasing the transcriptional activity of TFEB.This article is protected by copyright. All rights reserved
biotechnology & applied microbiology,biochemistry & molecular biology
What problem does this paper attempt to address?